Guo Chong, Zhan Bo, Li Meng-Yuan, Yue Li, Zhang Chao
Department of Obstetrics and Gynecology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Front Pharmacol. 2024 Jul 17;15:1400667. doi: 10.3389/fphar.2024.1400667. eCollection 2024.
Cervical cancer is the fourth most common cancer among females globally, with a high incidence and high mortality among females in developing countries. This retrospective case-control study aimed to investigate the association between oral contraceptives and cervical cancer, on which insufficient evidence still exists. To examine the association between oral contraceptives and cervical cancer based on 7,496 females aged over 20 years from the National Health and Nutrition Examination Survey, multivariable logistic regression conducted from 1999 to 2016 was used. Contraceptive use was positively associated with cervical cancer risk. In model 1 (unadjusted), a 195% increased risk of cervical cancer was observed among those who used oral contraceptives (odds ratio [OR] = 2.27, 95% confidence interval [CI] = 1.39-3.98, = 0.002) compared to those who did not. In addition, the ORs for the exposed population were 1.74 (95% CI = 1.05-3.08, = 0.041) and 1.93 (95% CI = 1.16-3.44, = 0.017) in model 2 (adjusted for age, race, and body mass index [BMI]) and model 3 (adjusted for education level, ratio of family income to poverty, drinking status, smoking status, number of pregnancies, age at first sex, number of sexual partners, and whether to receive the human papillomavirus (HPV) vaccine in addition to model 2), respectively. Furthermore, subgroup analyses stratified by age, smoking status, BMI, age at first sex, number of sexual partners, and whether to receive the HPV vaccine also revealed that oral contraceptives were significantly associated with cervical cancer. This study demonstrated that oral contraceptive use increased the risk of cervical cancer. In addition, the higher risk, including individuals older than 45 years, having a high BMI (≥30 kg/m), being current smokers, and having more than five sexual partners, may contribute to the development of cervical cancer.
宫颈癌是全球女性中第四大常见癌症,在发展中国家女性中发病率和死亡率都很高。这项回顾性病例对照研究旨在调查口服避孕药与宫颈癌之间的关联,目前关于这方面的证据仍然不足。为了基于美国国家健康与营养检查调查中7496名20岁以上女性的数据研究口服避孕药与宫颈癌之间的关联,采用了1999年至2016年进行的多变量逻辑回归分析。使用避孕药与宫颈癌风险呈正相关。在模型1(未调整)中,与未使用口服避孕药的女性相比,使用口服避孕药的女性患宫颈癌的风险增加了195%(优势比[OR]=2.27,95%置信区间[CI]=1.39 - 3.98,P = 0.002)。此外,在模型2(调整了年龄、种族和体重指数[BMI])和模型3(除模型2外,还调整了教育水平、家庭收入与贫困比例、饮酒状况、吸烟状况、怀孕次数、初次性行为年龄、性伴侣数量以及是否接种人乳头瘤病毒[HPV]疫苗)中,暴露人群的OR分别为1.74(95%CI = 1.05 - 3.08,P = 0.041)和1.93(95%CI = 1.16 - 3.44,P = 0.017)。此外,按年龄、吸烟状况、BMI、初次性行为年龄、性伴侣数量以及是否接种HPV疫苗进行分层的亚组分析也显示,口服避孕药与宫颈癌显著相关。这项研究表明,使用口服避孕药会增加患宫颈癌的风险。此外包括年龄超过45岁、BMI较高(≥30kg/m²)目前吸烟以及性伴侣超过五个等较高风险因素可能会促使宫颈癌的发生。